February 1, 2023
The American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST) sent a letter to Congress, requesting assistance in having islets regulated as organs in the U.S. Since 2000, the FDA has regulated allogenic islets for transplantation/infusion. Islets are recognized as drugs and, as a result, must follow a new drug development process. The outcome of this is that islets are not considered standard of care.
February 6, 2023
The American Society of Transplant Surgeons (ASTS) submitted comments on the 2024 Medicare Advantage (MA) Proposed Rule. Kidney transplantation is the treatment of choice for End Stage Renal Disease (ESRD), and ESRD-eligible Medicare beneficiaries became eligible to enroll in MA plans for the first time in 2021. A recent analysis conducted by Avalere recently found that just over 40,000 Medicare Fee-for-Service (FFS) patients with end-stage renal disease (ESRD) elected to enroll in Medicare Advantage (MA) during the 2021 open enrollment period.
July 18, 2023
Later this week, the Uniform Law Commission will meet to discuss proposed changes to the Uniform
Determination of Death Act (UDDA) and hold a first reading of the revised Uniform Declaration of Death
Act (rUDDA). On behalf of the
American Society of Transplant Surgeons (ASTS) and the undersigned
organizations, we write to request consideration not to move forward with the rUDDA.
Stay up to date on our advocacy work, addressing the issues that are important to you as a transplant professional.